Bharat Misra
,
MD
Dr. Misra was the class valedictorian in his high school and in college got the highest marks in chemistry and biology. He obtained his Bachelor of Medicine and Bachelor of Surgery degree from Gandhi Medical College in Hyderabad, India. He graduated First Class in all 13 subjects. Inspired by his elder brother, he came to the US and completed his internship, residency in internal medicine and fellowship in Gastroenterology at the Nassau University Medical Center, State University of New York at Stonybrook. He was Chief Resident for a year and was voted “Fellow of the Year” on graduation. After practicing for two years in upstate New York, he joined Borland Groover in 1997.
Dr. Misra enjoys the consultative aspects of Gastroenterology and Hepatology. His practice includes the full spectrum of endoscopy both inpatient and outpatient, diagnostic and therapeutic. Dr Misra has been actively involved in clinical research and has been a Principal Investigator of numerous clinical trials. His research interests include Fecal Microbiota Transplantation, C difficile infection, the Microbiome, obesity, GERD, colon cancer etc. He currently serves as the Medical Director of Encore Borland Groover Clinical Research (EBGCR.COM)
Dr. Misra was the Chief of Gastroenterology and Director of the Endoscopy Lab and currently serves on the Board of Directors at Memorial Hospital. He also serves on the Board of Directors at Jacksonville Center for Clinical Research.
Learn more about the data presented at Digestive Disease Week 2018 by Dr. Misra on a Microbiome therapy that induces remission in mild-to-moderate ulcerative colitis.
Henn MR, O’Brien EJ, Diao L, et al. A phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis. Gastroenterology. 2021;160(1):115-127.e30.
The Role of a Primary Care Physician in the Management of Inflammatory Bowel Disease. “Northeast Florida Medicine”, 2016.
Author of Chapter on Gastrointestinal Bleeding in the Manual of Critical Care Medicine, a multi author textbook published by the American College of Physicians (ACP)
Abstracts
CP101, an Investigational Orally Administered Microbiome Therapeutic was Effective for Prevention of Recurrent C. difficile Infection: Results from Open-Label PRISM-EXT Trial. DDW May 2022
CP101, an Investigational Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection: A Combined Analysis of the PRISM3 (randomized placebo-controlled) and PRISM-EXT (open-label extension) trials. DDW May 2022
CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results from a Randomized, Placebo-Controlled Trial. ACG 2021
Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection. ACG 2021
CP101 Engraftment Drives Efficacy: Results from a Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for Prevention of Recurrent C. difficile Infection. ACG 2021
SERES-101: A multiple dose phase 1b study to evaluate the efficacy, safety and microbiome dynamics of Seres-287 in subjects with mild-to-moderate Ulcerative Colitis (UC). ACG 2021
A multiple dose phase 1b study to evaluate the efficacy, safety and microbiome dynamics of Seres-287 in subjects with mild-to-moderate Ulcerative Colitis (UC). Abstract and Oral presentation at Digestive Diseases Week in Washington D.C. June 2018
Evaluation of health related quality of life in patients treated with RBX2660 (microbiota suspension) for recurrent C. difficile infection. Bharat K. Misra, M.D., Mayur S. Ramesh, MD, Mary Kay Sobcinski, RN, MHA. Borland Groover, Jacksonville FL; Henry Ford Health System, Detroit, MI; Rebiotix Inc., Roseville MN. ACG Philadelphia, Oct 2014
RBX2660 (microbiota suspension) for recurrent C difficile infection: 60 day interim analysis of the PUNCH CD phase 2 safety study. Mayur S Ramesh, MD, Bharat Misra, MD, Arnab Ray, MD, Robert Smith, MD, Mary Kay Sobcinski, RN,MHA
Henry Ford Hospital System, Detroit, MI; Borland Groover, Jacksonville FL; Ochsner Clinic, New Orleans, LA; Rebiotix Inc., Roseville MN. Philadelphia, Oct 2014
Budd-Chiari syndrome secondary to inferior venacava thrombosis in the setting of HIV Disease and Protein C deficiency: Bharat K. Misra, M.D. Abstract and poster, American College of Physicians, New York, NY.
Endoscopic treatment of Symptomatic Intraluminal migrated Marlex mesh in banded Roux-n-Y Gastric Bypass. H. Yasrebi, B.K. Misra. Abstract and Poster presentation at the American Society for Metabolic and Bariatric Surgery (ASMBS) meeting, Washington D.C. June 2009.
RESEARCH AND CLINICAL TRIALS
Principal Investigator
2017 Finch A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects with Recurrence of Clostridium difficile Infection
2017 Seres SERES 012 A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium difficile Infection (CDI) in Adults Who Have Received Antibacterial Drug Treatment for Recurrent CDI (RCDI)
2017 Seres SERES 013 An Open-Label Extension of Study Seres-012 Evaluating SER-109 in Adult Subjects with Recurrent Clostridium Difficile infection (RCDI)
2016 SERES-004 ECOSPOR: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of SER-109 to Prevent Recurrent Clostridium Difficile Infection
2016 SERES-005 An Open-label Extension of Study SERES-004 Evaluating SER-109 in Patients with Recurrent Clostridium difficile Infection
2016 SERES-101 A Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects with Mild-to-Moderate Ulcerative Colitis
2016 Second Phase 3 Randomized, 12Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
2015 Pharmacosmos P-Monofer-IDA-01 A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose in Subjects with Iron Deficiency Anaemia and who are Intolerant or Unresponsive to Oral Iron Therapy or who need Iron rapidly (PROVIDE) – Principal Investigator
2014 Rebiotix 2014-01 A Phase 2B Prospective, Randomized, Double-blinded, Placebo controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Treatment of Recurrent Clostridium difficile Infection. )
2014 Vibrant 179 CLD A multinational, multicenter, prospective double-blind, sham controlled, randomized study to assess the performance, efficacy and safety of Vibrating Capsule medical device in aiding relieving Constipated Individuals.
2013 Rebiotix 2013-001 A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Rebiotix Suspension for the Treatment of Recurrent Clostridium difficile-associated Diarrhea (CDAD) )
Sub-Investigator
2007 Abbott MO6-808 Crohn’s A Multi-center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn's Disease with Previous Exposure to Infliximab. - Sub-Investigator
2007 Salix RFIB2001 A Phase 2, Multicenter, Randomized double-blind, placebo-controlled study to assess the efficacy and safety of three different doses(275,550 and 1100MG) Of Rifaximin administered bid for either two or four weeks in the treatment of patients with diarrhea-associated irritable bowel syndrome.
2006 A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease. 2005 Alizyme ALTL1251/038/CL "A phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Renzapride in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS)
2005 Alizyme ATL1251/052/CL A Phase III Multicenter, Open Label Extension study to evaluate the long-term safety of Renzapride 4 mg. Once daily in women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS)
2005 Alizyme ALTL1251/038/CL A phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Renzapride in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS) 2005 Alizyme ALTL1251/038/CL A Phase III Multicenter, Open Label Extension study to evaluate the long-term safety of Renzapride 4 mg. Once daily in women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS)
2005 Alizyme ATL1251/052/CL A Phase III Multicenter, Open Label Extension study to evaluate the long-term safety of Renzapride 4 mg. Once daily in women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS)